- Director, Adult Sickle Cell Program, UH Seidman Cancer Center
Samuel Odame Anim MD, MSC, FAAP, is a hematologist and oncologist at University Hospitals and is the director of the Adult Sickle Cell Program at UH Seidman Cancer Center. He is board-certified in general pediatrics and pediatric hematology-oncology.
Dr. Anim earned a Bachelor of Science degree followed by his medical degree at Kwame Nkrumah University of Science and Technology in Kumasi, Ghana. He went on to earn a Master’s degree in hematology at the University of Westminster in London. Dr. Anim did his residency training in pediatrics at the Western Michigan University Homer Stryker M.D. School of Medicine (formerly Michigan State University Kalamazoo Center for Medical Studies), where he was named pediatric chief resident and earned the Resident Teaching Excellence Award. He then completed a fellowship in pediatric hematology/oncology and Washington University School of Medicine in St. Louis. His fellowship research was focused on asthma in sickle cell disease.
Prior to joining University Hospitals, Dr. Anim was an attending pediatric hematologist-oncologist at Sanford Roger Maris Cancer Center in Fargo, N.D. He was also the head of the Department of Pediatric Hematology Oncology and the co-director of the Sanford Bleeding Disorders and Sickle Cell Disease Clinic, providing lifespan care for individuals with sickle cell disease and bleeding disorders. In 2018, he was awarded the New to Sanford Physician Award, presented to a physician who is within his or her first five years at Sanford Health and has made a significant contribution in that time.
Dr. Anim is a member of several professional organizations and committees, including the American Academy of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology, and the Children’s Oncology Group. His clinical research interests include sickle cell disease, immunotherapy, and other areas of pediatric hematology/oncology. His experience includes being the principal investigator for the Childrens Oncology Group and several sickle cell clinical trials.
- Sickle Cell Disease
Certifications & Memberships
- Pediatric Hematology-Oncology - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Pediatric Hematology/Oncology
Pediatric Hematology/Oncology - St Louis Children's Hospital (2009 - 2012)
Residency | Pediatrics
Pediatrics - Western Michigan University Homer Stryker MD School Of Medicine (2006 - 2009)
Residency | Laboratory Medicine
Laboratory Medicine - Komfo Anokye Teaching Hospital (2004 - 2006)
Kwame Nkrumah University Of Science And Technology (2002)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Samuel Anim did not disclose any Outside Relationships with Industry.